Further evidence suggests that semaglutide reduces the risk of Alzheimer's disease

A new study provides real-world evidence supporting potential repurposing of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) used to treat type 2 diabetes and obesity to prevent Alzheimer's disease (AD ) can be used. Adults with type 2 diabetes who were…